BridgeBio Pharma LLC is 10% Owner at Eidos Therapeutics, Inc. (EIDX). They have made 3 open-market trades across 1 company since 2018, most recently 2018-12-10.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
3 open-market purchases totalling $17.1M since 2018, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| EIDX | 22,543,787 | $2.8B |
Shares reported on the most recent Form 4, priced at the 2018-12-13 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EIDX | BUY | 2018-12-10 | 2018-12-13 | $13.33 | $542K | -4.9% | -13.8% | +24.9% |
| EIDX | SELL · Routine | 2018-12-10 | 2018-12-12 | $13.33 | $542K | -8.0% | -11.0% | +25.6% |
| EIDX | BUY | 2018-12-06 | 2018-12-13 | $13.67 | $1.1M | -4.9% | -13.8% | +24.9% |
| EIDX | SELL · Routine | 2018-12-06 | 2018-12-10 | $13.67 | $1.1M | +4.6% | +0.7% | +22.8% |
| EIDX | BUY | 2018-12-05 | 2018-12-06 | $14.01 | $15.5M | +8.9% | +4.7% | +32.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.